Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRA_23653 is a synthetic small molecule belonging to the class of phenylbenzimidazoles. Its chemical structure features a benzimidazole core with phenyl and hydroxy substitutions and an aminoethyl side chain. The compound has been studied primarily as a research tool for binding selectivity and affinity profiling against various biological targets, but there is no evidence it has reached advanced clinical development or approval as a therapeutic drug. Its mechanism of action or primary pharmacological target is not clearly established in the public domain[1][2][9]. It appears in chemical databases and patent literature as an experimental compound used for receptor binding studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CRA_23653.